Responses
Regular and young investigator award abstracts
Clinical trials in progress
343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)
Compose a Response to This Article
Other responses
No responses have been published for this article.
